Bevacizumab andWeekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

被引：14

作者：

Francini, Filippo ^{[1
]}

Pascucci, Alessandra ^{[2
]}

Francini, Edoardo ^{[2
]}

Bargagli, Gianluca ^{[2
]}

Conca, Raffaele ^{[2
]}

Licchetta, Antonella ^{[2
]}

Roviello, Giandomenico ^{[2
]}

Martellucci, Ignazio ^{[2
]}

Chiriaco, Giorgio ^{[2
]}

Miano, Salvatora Tindara ^{[2
]}

Marzocca, Giuseppe ^{[3
]}

Manganelli, Antonio ^{[4
]}

Ponchietti, Roberto ^{[5
]}

Savelli, Vinno ^{[6
]}

Petrioli, Roberto ^{[2
]}

机构：

[1] Univ Siena, Dept Odontostomatol & Maxillo Facial Surg, I-53100 Siena, Italy

[2] Univ Siena, Med Oncol, Policlinico Scotte,Viale Bracci 11, I-53100 Siena, Italy

[3] Univ Siena, Gen Surg, I-53100 Siena, Italy

[4] Univ Siena, Urol Surg, I-53100 Siena, Italy

[5] Univ Siena, Genitourinary Unit, I-53100 Siena, Italy

[6] Univ Siena, Dept Surg, I-53100 Siena, Italy

来源：

PROSTATE CANCER | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/258689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95% CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.

引用

页数：7

共 50 条

[1] Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
Pal, Sumanta K.
Lewis, Brian
Sartor, Oliver
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 583 - +
[2] Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
Mountzios, Ioannis
Bournakis, Evangelos
Efstathiou, Eleni
Varkaris, Andreas
Wen, Sijin
Chrisofos, Michael
Deliveliotis, Charalambos
Alamanis, Christos
Anastasiou, Ioannis
Constantinides, Constantine
Karadimou, Alexandra
Tsiatas, Marinos
Papadimitriou, Christos
Bamias, Aristotelis
Dimopoulos, Meletios A.
[J]. UROLOGY, 2011, 77 (03) : 682 - 687
[3] Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
Cheung, F. Y.
Leung, K. C.
Ngan, Roger K. C.
[J]. HONG KONG MEDICAL JOURNAL, 2013, 19 (03) : 237 - 241
[4] Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
Vaishampayan, Ulka N.
Fontana, Joseph
Heilbrun, Lance K.
Smith, Daryn
Heath, Elisabeth
Dickow, Brenda
Figg, William D.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 31.e25 - 31.e33
[5] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
Thomson, David
Charnley, Natalie
Parikh, Omi
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
[6] Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
Cornford, Philip
[J]. JOURNAL OF CLINICAL UROLOGY, 2010, 3 (06) : 225 - 230
[7] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
Gernone, A.
Pagliarulo, A.
Calderoni, G.
Pagliarulo, V.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[8] Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.
Shepard, D. R.
Weil, A.
Garcia, J. A.
Dreicer, R.
Raghavan, D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[9] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
Thomson, Alastair
Pollard, Adam
Mark, Frances May
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[10] CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
Wissing, Michel D.
Coenen, Jules L. L. M.
van den Berg, Pieter
Westgeest, Hans M.
van den Eertwegh, Alfons J. M.
van Oort, Inge M.
Bos, Monique M.
Bergman, Andre M.
Hamberg, Paul
ten Tije, Albert J.
Los, Maartje
Lolkema, Martijn P. J. K.
de Wit, Ronald
Gelderblom, Hans
[J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (06) : E760 - E772

← 1 2 3 4 5 →